IL-6 has been shown to trigger Th17 cell differentiation via STAT3 activation, thus promoting inflammation in IBD patients, whereas leukemia inhibitory factor (LIF)—a cytokine of the IL-6 family—effectively inhibits Th17 accumulation and promotes damaged intestinal epithelium repair [45]. The gene discussed is IL6; the disease is inflammatory bowel disease.